Mirtazapine, in orodispersible form, for patients with preoperative psychological distress: A pilot study

详细信息    查看全文

• 作者：Wei-Han Chou¹ ; Feng-Sheng Lin¹ ; Chih-Peng Lin¹ ; Wen-Ying Lin¹ ; Jr-Chi Yie² ; Wei-Zen Sun¹ ; ^{wzsun@ntu.edu.tw" class="auth_mail" title="E-mail the corresponding author}
• 关键词：antidepressant ; insomnia ; mirtazapine ; perioperative anxiety ; perioperative depression
• 刊名：Acta Anaesthesiologica Taiwanica
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：54
• 期：1
• 页码：16-23
• 全文大小：646 K

文摘

Perioperative psychological distress is associated with preoperative anxiety, depression, and postoperative pain. Mirtazapine is effective as an antidepressant, anxiolytic agent, and sleep enhancer. Moreover, mirtazapine can be made as orodispersible tablets with a fast onset for patients in nil per os status. This study is to determine whether mirtazapine can help psychologically distressed patients reduce perioperative anxiety, depression, and postoperative pain.

Materials and methods

Patients with preoperative psychological distress, undergoing major abdominal surgery, were inquired and assigned to two groups according to their own choice. In the treatment group, patients could choose to take orodispersible mirtazapine 30 mg at each night from Preoperative Day 0 to Postoperative Day 3. There was no other intervention in the nontreatment group. Hospital Anxiety and Depression Scale (HADS), Athens Insomnia Scale (AIS), and pain scores were accessed on the day before operation (Day 0), and on the 1^st day (Day 2) and 3^rd day (Day 4) after operation. We compared the HADS, AIS, and pain scores, and morphine consumptions between the two groups on a daily basis. Marginal regression models were fitted to our correlated longitudinal data alone with the generalized estimating equations method to estimate the population average effects of time-varying mirtazapine usage on the mean values of HADS, AIS, and pain scores, and daily morphine consumptions.

Results

From September 2007 to December 2008, 86 patients agreed to be enrolled and 79 of them completed the study. Propensity scores and multivariate analysis showed that mirtazapine reduced HADS scores of patients in 2 days. Trial results indicated that mirtazapine lowered the AIS day index and tended to decrease night index as well. Mirtazapine may reduce patients' morphine consumption, but this effect was not statistically significant (p = 0.2).

Conclusion

Mirtazapine helps reduce anxiety, depression, and insomnia scores for patients with perioperative psychological distress.